Study examines the efficacy of anastrozole in preventing breast cancer in postmenopausal women at high risk, focusing on the role of baseline estradiol levels and their impact on treatment outcomes.

This prospective, randomized, multicenter open-label phase III study assessed the effect of extending anastrozole treatment for an additional 5 years in postmenopausal patients who were disease-free ...

In the efficacy study, the patients with advanced breast cancer received anastrozole 0.5 or 1 mg/day for 12 weeks or more and tumour response was determined at 4-week intervals during treatment.

Like the better-known tamoxifen, anastrozole was first used to treat breast cancer. Then, because risk doesn’t end with treatment, the hormone-blocking drug was also prescribed to prevent cancer ...

Studying the possible association between AI and cognitive dysfunction has accelerated over the past 7 years. A pilot study using neuropsychological testing from the Arimidex, Tamoxifen, Alone or ...

Women post-menopause with ‘strong family history’ of breast cancer encouraged speak to GP about drug, expert says ...

Blood hormone levels key to identifying which post-menopausal women will benefit most from taking anastrozole to prevent ... was approved by NICE as a preventive treatment for some woman at high ...

Anastrozole, a daily pill to prevent breast cancer, will now be available to thousands of more women in the UK after being cleared for wider use.. The drug has been used to treat hormone-driven ...

The drug, called anastrozole, isn’t new: it has been available for years as a breast-cancer treatment and was already recommended for prevention by the country’s health-cost regulator, ...